Skip to main content

Table 1 The association between clinicopathological parameters and expression of c-MYC and ß-catenin in 367 CRC patients (cohort1)

From: Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ß-catenin

 

Total

c-Myc IHC

P-Value

c-Myc RNA ISH (score)

P-Value

ß-catenin IHC (%)

P-Value

Negative

Positive

Negative

Positive

Negative

Positive

Age

 mean

64.2

64.6

63.9

0.537

63.4

64.7

0.334

64.1

63.7

0.257

Sex

 male

205

89 (43.4 %)

116 (56.6 %)

0.431

72 (35.1 %)

133 (64.9 %)

0.720

82 (40.0 %)

123 (60.0 %)

0.924

 female

162

77 (47.5 %)

85 (52.5 %)

 

54 (33.3 %)

108 (66.7 %)

 

64 (39.5 %)

98 (60.5 %)

 

Location

 cecum

13

12 (92.3 %)

1 (7.7 %)

0.002

12 (92.3 %)

1 (7.7 %)

0.039

11 (84.6 %)

2 (15.4 %)

0.103

 ascending colon

55

39 (70.9 %)

16 (29.1 %)

 

37 (67.3 %)

18 (32.7 %)

 

36 (65.5 %)

19 (34.5 %)

 

 hepatic flexure

22

14 (63.6 %)

8 (36.4 %)

 

17 (77.3 %)

5 (22.7 %)

 

14 (63.6 %)

8 (36.4 %)

 

 transverse colon

16

10 (62.5 %)

6 (37.5 %)

 

11 (68.8 %)

5 (31.3 %)

 

11 (68.8 %)

5 (31.3 %)

 

 splenic flexure

6

5 (83.3 %)

1 (16.7 %)

 

4 (66.7 %)

2 (33.3 %)

 

4 (66.7 %)

2 (33.3 %)

 

 descending colon

18

15 (83.3 %)

3 (16.7 %)

 

15 (83.3 %)

3 (16.7 %)

 

13 (72.2 %)

5 (27.8 %)

 

 sigmoid colon

114

53 (46.5 %)

61 (53.5 %)

 

64 (56.1 %)

50 (43.9 %)

 

62 (54.4 %)

52 (45.6 %)

 

 rectum

123

71 (57.7 %)

52 (42.3 %)

 

89 (72.4 %)

34 (27.6 %)

 

61 (49.6 %)

62 (50.4 %)

 

pT stage

 0–2

58

14 (24.1 %)

44 (75.9 %)

<0.001

14 (24.1 %)

44 (75.9 %)

0.075

17 (29.3 %)

41 (70.7 %)

0.076

 3–4

309

152 (49.2 %)

157 (50.8 %)

 

112 (36.2 %)

197 (63.8 %)

 

129 (41.7 %)

180 (58.3 %)

 

Differentiation

 LG

331

142 (42.9 %)

189 (57.1 %)

0.007

101 (30.5 %)

230 (69.5 %)

<0.001

124 (37.5 %)

207 (62.5 %)

0.006

 HG

36

24 (66.7 %)

12 (33.3 %)

 

25 (69.4 %)

11 (30.6 %)

 

22 (61.1 %)

14 (38.9 %)

 

LN metastasis

 absent

168

67 (39.9 %)

101 (60.1 %)

0.058

58 (34.5 %)

110 (65.5 %)

0.943

63 (37.5 %)

105 (62.5 %)

0.412

 present

199

99 (49.7 %)

100 (50.3 %)

 

68 (34.2 %)

131 (65.8 %)

 

83 (41.7 %)

116 (58.3 %)

 

Lymphatic invasion

 absent

158

63 (39.9 %)

95 (60.1 %)

0.073

51 (32.3 %)

107 (67.7 %)

0.471

61 (38.6 %)

97 (61.4 %)

0.689

 present

209

103 (49.3 %)

106 (50.7 %)

 

75 (35.9 %)

134 (64.1 %)

 

85 (40.7 %)

124 (59.3 %)

 

Perineural invasion

 absent

154

49 (31.8 %)

105 (68.2 %)

0.025

78 (30.7 %)

176 (69.3 %)

0.028

99 (39.0 %)

155 (61.0 %)

0.636

 present

113

61 (54.0 %)

52 (46.0 %)

 

48 (42.5 %)

65 (57.5 %)

 

47 (41.6 %)

66 (58.4 %)

 

Venous invasion

 absent

296

133 (44.9 %)

163 (55.1 %)

0.814

101 (34.1 %)

195 (65.9 %)

0.862

121 (40.9 %)

175 (59.1 %)

0.381

 present

71

33 (46.5 %)

38 (53.5 %)

 

25 (35.2 %)

46 (64.8 %)

 

25 (35.2 %)

46 (64.8 %)

 

Tumor border

 expanding

60

25 (41.7 %)

35 (58.3 %)

0.544

27 (45.0 %)

33 (55.0 %)

0.057

24 (40.0 %)

36 (60.0 %)

0.970

 infiltrative

307

141 (45.9)

166 (54.1 %)

 

99 (32.2 %)

208 (67.8 %)

 

122 (39.7 %)

185 (60.3 %)

 

Size (cm)

 mean

5.3

5.8

4.8

<0.001

6.0

4.9

<0.001

5.6

5.0

0.007

Distant metastasis

 absent

299

131 (43.8 %)

168 (56.2 %)

0.252

97 (32.4 %)

202 (67.6 %)

0.110

115 (38.5 %)

184 (61.5 %)

0.278

 present

68

35 (51.5 %)

33 (48.5 %)

 

29 (42.6 %)

39 (57.4 %)

 

31 (45.6 %)

37 (54.4 %)

 

pTNM stage

 I, II

162

64 (39.5 %)

98 (60.5 %)

0.050

55 (34.0 %)

107 (66.0 %)

0.891

59 (37.1 %)

100 (62.9 %)

0.399

 III, IV

205

102 (49.8 %)

103 (50.2 %)

 

71 (34.6 %)

134 (65.4 %)

 

85 (41.5 %)

120 (58.5 %)

 

MSI status

 MSS/MSI-L

323

141 (43.7 %)

182 (56.3 %)

0.490

105 (32.5 %)

218 (67.5 %)

0.019

177 (54.8 %)

146 (45.2 %)

<0.001

 MSI-H

32

16 (50.0 %)

16 (50.0 %)

 

17 (53.1 %)

15 (46.9 %)

 

28 (87.5 %)

4 (12.5 %)

 

Chemotherapy status

 none

97

41 (42.3 %)

56 (57.7 %)

<0.001

67 (69.1 %)

30 (30.9 %)

0.748

49 (50.5 %)

48 (49.5 %)

0.175

 pre-

0

0 (0.0 %)

0 (0.0 %)

 

0 (0.0 %)

0 (0.0 %)

 

0 (0.0 %)

0 (0.0 %)

 

 post-

269

177 (65.8 %)

92 (34.2 %)

 

181 (67.3 %)

88 (32.7 %)

 

162 (60.2 %)

107 (39.8 %)

 

 Pre- and post-

1

1 (100.0 %)

0 (0.0 %)

 

1 (100.0 %)

0 (0.0 %)

 

1 (100.0 %)

0 (0.0 %)

 
  1. P-values are calculated by using χ2-test or Fisher’s exact test
  2. Abbreviations: CRC colorectal cancer, T tumor, LG low grade, HG high grade, LN lymph node, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, IHC immunohistochemistry, ISH in-situ hybridization